Critical Survey: Pulse Biosciences (PLSE) & The Competition

Pulse Biosciences (NASDAQ:PLSE) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Pulse Biosciences to related businesses based on the strength of its profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Valuation and Earnings

This table compares Pulse Biosciences and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pulse Biosciences	$350,000.00	-$72.78 million	-45.16
Pulse Biosciences Competitors	$1.89 billion	$137.77 million	9.47

Pulse Biosciences’ rivals have higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Pulse Biosciences and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1	0	5	1	2.86
Pulse Biosciences Competitors	4270	10539	18313	828	2.46

Pulse Biosciences presently has a consensus target price of $66.60, indicating a potential upside of 24.98%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.07%. Given Pulse Biosciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe Pulse Biosciences is more favorable than its rivals.

Institutional and Insider Ownership

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Pulse Biosciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Pulse Biosciences Competitors	-276.78%	-149.08%	-21.73%

Volatility and Risk

Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Pulse Biosciences’ rivals have a beta of 2.70, indicating that their average stock price is 170% more volatile than the S&P 500.

Summary

Pulse Biosciences beats its rivals on 7 of the 13 factors compared.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.